CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-01 | TAHL CINDY General Counsel and Secretary | Sale | −25,000 | $22.96 | $574K | 189,151 |
| 2022-06-01 | TAHL CINDY General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −25,000 | 54,210 | ||
| 2022-04-22 | Wolchko J Scott President and CEO | Option exercise | +10,000 | $2.70 | $27K | 441,546 |
| 2022-04-22 | Wolchko J Scott President and CEO | Sale | −9,162 | $34.54 | $316K | 432,384 |
| 2022-04-22 | Wolchko J Scott President and CEO | Sale | −838 | $35.15 | $29K | 431,546 |
| 2022-04-22 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −10,000 | $2.70 | $27K | 36,246 |
| 2022-04-21 | Wolchko J Scott President and CEO | Option exercise | +30,000 | $2.70 | $81K | 461,546 |
| 2022-04-21 | Wolchko J Scott President and CEO | Sale | −22,715 | $34.57 | $785K | 438,831 |
| 2022-04-21 | Wolchko J Scott President and CEO | Sale | −4,062 | $35.73 | $145K | 434,769 |
| 2022-04-21 | Wolchko J Scott President and CEO | Sale | −2,220 | $36.70 | $81K | 432,549 |
| 2022-04-21 | Wolchko J Scott President and CEO | Sale | −1,003 | $37.90 | $38K | 431,546 |
| 2022-04-21 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | $2.70 | $81K | 46,246 |
| 2022-04-19 | Chu Yu-Waye Chief Medical Officer | Sale | −4,062 | $35.37 | $144K | 151,033 |
| 2022-04-01 | TAHL CINDY General Counsel and Secretary | Option exercise | +19,433 | $4.84 | $94K | 208,584 |
| 2022-04-01 | TAHL CINDY General Counsel and Secretary | Option exercise | +5,567 | $6.55 | $36K | 214,151 |
| 2022-04-01 | TAHL CINDY General Counsel and Secretary | Sale | −25,000 | $38.85 | $971K | 189,151 |
| 2022-04-01 | TAHL CINDY General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −19,433 | 8,195 | ||
| 2022-04-01 | TAHL CINDY General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −5,567 | 79,210 | ||
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Option exercise | +25,000 | $2.73 | $68K | 204,834 |
| 2022-03-14 | Valamehr Bahram Chief R&D Officer | Sale | −16,678 | $30.36 | $506K | 188,156 |
Page 11 of 26 · 503 trades